Liver transplantation for XXXX .

@entity1 @entity500 @entity879 @entity409 @entity102 @entity134 @entity230 @entity99 @entity775
AIMS: The aim of this study was to analyse long-term outcomes of @entity1 with liver transplantation for @entity775 and to determine if @entity879 ( @entity879 ) at presentation was a predictor of outcome after ortothopic liver transplantation. @entity1 AND METHODS: Between April 1990 and October 2002, 18 @entity1 with @entity775 underwent 21 liver transplants. Three @entity1 were excluded because of coexisting causes of @entity99 . Seven @entity1 had @entity879 and eight @entity1 had @entity102 . The initial immunosuppressive regimen was cyclosporine based in 80%, and all but one @entity1 received @entity230 or @entity500 . RESULTS: Mean age at time of transplant was 44.2+/-15.5 years. @entity1 were followed for 38.9+/-29.6 months. Five @entity1 (33.3%) had seven episodes of acute rejection (two @entity134 -resistant). Three @entity1 developed chronic rejection. One @entity1 displayed histologically proven recurrent @entity775 . Actuarial @entity1 and graft survival rates at 1 and 5 years were 80% and 56% and 78.6% and 51%, respectively. No differences in the clinical characteristics of the @entity1 , rates of acute or chronic rejection episodes, end biliary or arterial complications were observed between @entity879 and chronic @entity775 . The study suggests a better survival for autoimmune @entity879 (P=.003). CONCLUSIONS: Liver transplant is indicated for @entity1 displaying @entity409 and @entity879 with similar clinical courses at however, @entity1 with @entity879 at presentation had better survivals.
